Nordic Business Report-April 28, 2006-BioTie Therapies Corporation signs distribution agreement with Britannia Pharmaceuticals
(C)1994-2006 M2 COMMUNICATIONS LTD http://www.m2.com
Finnish pharmaceutical company BioTie Therapies Corporation said on Friday (28 April) that it had signed a marketing and distribution agreement with the UK-based pharmaceutical company Britannia Pharmaceuticals Limited.
Under the agreement BioTie has granted Britannia an exclusive licence to market and distribute nalmefene as a prescription medicine for the treatment of substance abuse disorders and impulse control disorders in the United Kingdom and Ireland.
Britannia would purchase nalmefene finished product from BioTie and Britannia would be responsible for its registration, sales and marketing.
((Comments on this story may be sent to email@example.com))